Plain-English translation of NCT07582354 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The MMAPPIN' Study is collecting blood samples and genetic information from people with multiple myeloma — a blood cancer affecting plasma cells. By studying the DNA and RNA in patients' blood and tumor cells, researchers hope to create a detailed map of the disease that shows why it behaves differently in different people and how to predict which treatments will work best.
Multiple myeloma affects patients very differently — some respond well to treatment while others don't, and some relapse quickly while others stay stable. This study exists to understand the biological reasons behind these differences, so that in the future, doctors can choose treatments tailored to each patient's specific disease.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow researchers to collect blood samples and review your medical records — both past information and ongoing clinical data. Your genetic material would be analyzed using advanced sequencing techniques, and this information would be combined with details about your disease progression and how you've responded to treatments. All your information would be kept confidential and securely stored to build a comprehensive research database.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Italy
Enrollment target
~520 participants
Started
October 2025
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Carolina Terragna, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.